Lars Fruergaard Jorgensen becomes CEO as sales flatline at DKK 111.7 billion

Lars Fruergaard Jorgensen became chief executive of Novo Nordisk in 2017, a year when the Danish drugmaker's net sales were essentially flat compared with the prior year, coming in at DKK 111.7 billion, with operating profit of DKK 49.0 billion ^[1]. That same year, the U.S. Food and Drug Administration approved Ozempic, the injectable semaglutide drug for type 2 diabetes that would later become one of the best-selling medicines in the world ^[1].

The flat sales figures reflect a company facing pricing pressure and competition in its core insulin business at the time, according to the annual report filed with U.S. regulators ^[1]. Operating profit of DKK 49.0 billion in that period shows the company was still highly profitable even as top-line growth stalled ^[1]. The filing, a Form 20-F submitted to the U.S. Securities and Exchange Commission, covers Novo Nordisk's financial results and corporate structure as a foreign private issuer listed on the New York Stock Exchange ^[1].

Ozempic's approval that year did not immediately show up in the flat 2017 sales numbers, since new drugs typically take time to build prescribing volume and market share ^[1]. But the approval marked the starting point for a drug that would go on to reshape how diabetes, and later obesity, is treated in the United States. The filing does not detail Ozempic's specific 2017 sales figures separately from the company's total revenue ^[1].

Why it matters for patients

For people who use Ozempic, Wegovy, or other GLP-1 medicines today, this moment in 2017 is the origin point. The leadership change and the initial U.S. approval of Ozempic set in motion the corporate strategy and drug pipeline that would later produce Wegovy for weight loss and expand access to semaglutide across the country ^[1]. Understanding that Ozempic was approved amid otherwise flat company sales helps explain why the drug's later explosive growth was such a turnaround for Novo Nordisk's business ^[1].

Patients should also understand that corporate financial performance, like flat sales or profit margins, does not directly indicate a drug's safety or effectiveness. Those details come from separate clinical trial data and FDA review, not from a company's balance sheet. The 2017 numbers cited here reflect Novo Nordisk's overall corporate results, not data specific to how Ozempic performed once it reached pharmacies and patients ^[1].

The timing also matters for anyone tracking how long a GLP-1 drug has been on the market. Ozempic has been available in the U.S. since 2017, giving it a longer track record than newer entrants in the same drug class ^[1]. That history can be relevant for patients and doctors weighing which GLP-1 medicine has more years of real-world use behind it.

What happens next

The source filing does not specify follow-up milestones beyond the 2017 data and leadership change ^[1]. It is not yet known from this filing how quickly Ozempic sales grew in the years immediately following its 2017 approval, or what specific strategic changes Jorgensen made as CEO in his first years leading the company ^[1]. Those details would require later annual reports or company disclosures not included in this filing.